US 11,891,457 B2
Peptide-compound cyclization method
Shiori Kariyuki, Shizuoka (JP); Takeo Iida, Kanagawa (JP); Miki Kojima, Kanagawa (JP); Ryuichi Takeyama, Shizuoka (JP); Mikimasa Tanada, Shizuoka (JP); Tetsuo Kojima, Kanagawa (JP); Hitoshi Iikura, Shizuoka (JP); Atsushi Matsuo, Shizuoka (JP); Takuya Shiraishi, Shizuoka (JP); Takashi Emura, Shizuoka (JP); Kazuhiko Nakano, Shizuoka (JP); Koji Takano, Shizuoka (JP); Kousuke Asou, Shizuoka (JP); Takuya Torizawa, Shizuoka (JP); Ryusuke Takano, Shizuoka (JP); Nozomi Hisada, Shizuoka (JP); Naoaki Murao, Shizuoka (JP); Atsushi Ohta, Kanagawa (JP); Kaori Kimura, Kanagawa (JP); Yusuke Yamagishi, Kanagawa (JP); and Tatsuya Kato, Tokyo (JP)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed on Sep. 3, 2020, as Appl. No. 17/011,815.
Application 17/011,815 is a continuation of application No. 15/166,550, filed on May 27, 2016, abandoned.
Application 15/166,550 is a continuation of application No. 14/368,564, granted, now 9,409,952, issued on Aug. 9, 2016, previously published as PCT/JP2012/084103, filed on Dec. 28, 2012.
Claims priority of application No. 2011-288865 (JP), filed on Dec. 28, 2011; and application No. 2012-156943 (JP), filed on Jul. 12, 2012.
Prior Publication US 2021/0061860 A1, Mar. 4, 2021
Int. Cl. C07K 7/64 (2006.01); C07K 1/113 (2006.01); C12P 21/02 (2006.01); C07K 7/08 (2006.01); C07K 19/00 (2006.01); C07H 21/04 (2006.01); C07K 5/087 (2006.01); C07K 5/103 (2006.01); C07K 7/06 (2006.01); C07K 11/00 (2006.01); C07K 11/02 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/64 (2013.01) [C07H 21/04 (2013.01); C07K 1/113 (2013.01); C07K 5/0812 (2013.01); C07K 5/1013 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 11/00 (2013.01); C07K 11/02 (2013.01); C07K 19/00 (2013.01); C12P 21/02 (2013.01); A61K 38/00 (2013.01)] 14 Claims
 
1. A peptide compound having a cyclic portion, wherein:
(i) the peptide compound contains a cyclic portion composed of 5 to 12 amino acids and amino acid analog residues in total, and has 9 to 13 amino acids and amino acid analogs in total,
(ii) the peptide compound contains at least three N-alkylated amino acids, wherein the N-alkylated amino acids are N-methylated amino acids,
(iii) the peptide compound has a ClogP value of 8 to 15, and
(iv) the peptide compound has at least one amide bond formed between a side chain of an amino acid or an amino acid analog and a nitrogen atom of the main chain of another amino acid or amino acid analog,
wherein the peptide compound comprises an amide bond formed between a side chain of an optionally substituted glutamic acid or an optionally substituted aspartic acid and a nitrogen atom of the main chain of another amino acid.